JP2023542065A5 - - Google Patents
Info
- Publication number
- JP2023542065A5 JP2023542065A5 JP2022580314A JP2022580314A JP2023542065A5 JP 2023542065 A5 JP2023542065 A5 JP 2023542065A5 JP 2022580314 A JP2022580314 A JP 2022580314A JP 2022580314 A JP2022580314 A JP 2022580314A JP 2023542065 A5 JP2023542065 A5 JP 2023542065A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- cancer
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025264238A JP2026048890A (ja) | 2020-06-24 | 2025-12-18 | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043528P | 2020-06-24 | 2020-06-24 | |
| US63/043,528 | 2020-06-24 | ||
| PCT/IB2021/055547 WO2021260578A1 (en) | 2020-06-24 | 2021-06-23 | Combination of antibody-drug conjugate and cdk9 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025264238A Division JP2026048890A (ja) | 2020-06-24 | 2025-12-18 | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542065A JP2023542065A (ja) | 2023-10-05 |
| JP2023542065A5 true JP2023542065A5 (cg-RX-API-DMAC7.html) | 2024-06-24 |
| JP7794766B2 JP7794766B2 (ja) | 2026-01-06 |
Family
ID=76971937
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580314A Active JP7794766B2 (ja) | 2020-06-24 | 2021-06-23 | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
| JP2025264238A Pending JP2026048890A (ja) | 2020-06-24 | 2025-12-18 | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025264238A Pending JP2026048890A (ja) | 2020-06-24 | 2025-12-18 | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230233540A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171654A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7794766B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116615248A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202216207A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021260578A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3249707A1 (en) * | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems and methods for modulating a target gene |
| CN116712561A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | 含n-亚甲基酰胺连接子的抗体-药物偶联物 |
| WO2025054996A1 (en) * | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| WO2025162211A1 (zh) * | 2024-01-29 | 2025-08-07 | 正大天晴药业集团股份有限公司 | 抗her2抗体药物偶联物治疗胃癌的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| JP6282232B2 (ja) | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド,ボルティモア | 抗体及びそのFcフラグメントの酵素化学的糖鎖改変 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| TR201909286T4 (tr) | 2015-06-29 | 2019-07-22 | Astrazeneca Ab | CDK9 inhibitörleri olarak polisiklik amid türevleri. |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| US20210101881A1 (en) * | 2018-02-12 | 2021-04-08 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Pyrimidine compound, preparation method thereof and medical use thereof |
-
2021
- 2021-06-23 CN CN202180050400.1A patent/CN116615248A/zh active Pending
- 2021-06-23 WO PCT/IB2021/055547 patent/WO2021260578A1/en not_active Ceased
- 2021-06-23 US US18/012,434 patent/US20230233540A1/en active Pending
- 2021-06-23 TW TW110122958A patent/TW202216207A/zh unknown
- 2021-06-23 EP EP21743249.1A patent/EP4171654A1/en active Pending
- 2021-06-23 JP JP2022580314A patent/JP7794766B2/ja active Active
-
2025
- 2025-12-18 JP JP2025264238A patent/JP2026048890A/ja active Pending